Analyses / JNJ
Defensive mega-cap pharma trading near the upper half of its 52-week range, with premium trailing valuation and mixed growth signals.
A free account reveals JNJ's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Forward P/E of 24.7x (price vs next-year earnings) is well below the trailing 41.1x, implying expected earnings recovery. EPS growth of 17.9% outpaces 5.6% revenue growth. Operating margin 34.6% and net margin 28.5% are strong. Beta of 0.17 and a 3.1% dividend yield suggest low sensitivity to broad market swings. If the stock holds above the 272.6 day low, a retest of the 52-week high near 290.2 is possible.
▼ Bear Case
Trailing P/E of 41.1x, P/B of 6.1x and P/S of 7.0x leave little valuation cushion if growth slows. Revenue growth of 5.6% (5-year average 2.7%) is modest for the multiple. Insiders sold 1.54M shares versus 1.43M bought across 266 transactions. Current ratio of 1.03 and quick ratio of 0.69 are thin. Shares fell 2.2% on the day and trade about 6% below the 52-week high.
Valuation
FULL PREMIUM — score 35/100
Trailing multiples are rich, while forward P/E and margins are more supportive.
Technical Levels
Support · $272.58 (Day low) · $275.55 (Day open)
Resistance · $278.70 (Prior close) · $290.25 (52-week high)
RSI: Not available in payload
Financial Health
Score 60/100. Profitability is strong, but liquidity ratios are thin and leverage data is missing from the payload.
Catalysts
| Revenue growth acceleration above the 5.6% trailing rate | Next quarterly report (date not in payload) | high |
| Reclaim of the 290.25 52-week high | Within 1 to 3 months if momentum resumes | medium |
| Continued insider net selling | Ongoing Form 4 filings | low |
Risk Flags
See JNJ's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock JNJ free →Recent News
- Should Biogen Stock Holders Look At Amgen Instead?Yahoo
- What State Street Health Care SPDR (XLV) Sold: Eli Lilly Leads on Nov. 17Yahoo
- Invest $25,000 in These 4 Dividend Stocks to Start Building Retirement IncomeYahoo
- Is Lilly Stock's Winning Streak Skill Or Luck?Yahoo
- Global Multiport Surgical Robot Market 2026 Report: Trends and Forecast to 2030 | Capitalize on 19.1% CAGR as Intuitive Surgical, Medtronic, J&J and CMR Surgical Advance AI SurgeryYahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full JNJ analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
JNJ FAQ
Is JNJ a buy right now?
Johnson & Johnson's current read is a Quality defensive, range-bound setup with medium confidence over a 1-3 months horizon. Valuation: FULL PREMIUM. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is JNJ overvalued?
FULL PREMIUM (valuation score 35/100). Trailing multiples are rich, while forward P/E and margins are more supportive.
What are the risks of buying JNJ?
Trailing P/E of 41.1x, P/B of 6.1x and P/S of 7.0x leave little valuation cushion if growth slows. Revenue growth of 5.6% (5-year average 2.7%) is modest for the multiple. Insiders sold 1.54M shares versus 1.43M bought across 266 transactions. Current ratio of 1.03 and quick ratio of 0.69 are thin. Shares fell 2.2% on the day and trade about 6% below the 52-week high.